Human papilloma virus load and PD-1/PD-L1, CD8⁺ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016; 66:7-30; PMID:28055103; http://dx.doi.org/10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, Thomas CR, Jr., Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Jama 2008; 299:1914-21; PMID:18430910; http://dx.doi.org/10.1001/jama.299.16.1914
   PubMed Web of Science ®Google Scholar
• James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 2013; 14:516-24; PMID:23578724; http://dx.doi.org/10.1016/S1470-2045(13)70086-X
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D, ESMO; ESSO; ESTRO. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 2014; 111:330-9; PMID:24947004; http://dx.doi.org/10.1016/j.radonc.2014.04.013
   PubMed Web of Science ®Google Scholar
• De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Euro J Cancer 2009; 45:2632-9; PMID:19709878; http://dx.doi.org/10.1016/j.ejca.2009.07.019
   PubMed Web of Science ®Google Scholar
• Bernardi MP, Ngan SY, Michael M, Lynch AC, Heriot AG, Ramsay RG, Phillips WA. Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. Lancet Oncol 2015; 16:e611-21; PMID:26678214; http://dx.doi.org/10.1016/S1470-2045(15)00292-2
   PubMed Web of Science ®Google Scholar
• Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Hogdall E, Geertsen PF, Havsteen H. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on cancer stages I to III carcinoma of the anal canal. J Clin Oncol 2014; 32:1812-7; PMID:24821878; http://dx.doi.org/10.1200/JCO.2013.52.3464
   PubMed Web of Science ®Google Scholar
• Kim JY, Park S, Nam BH, Roh JW, Lee CH, Kim YH, Shin HJ, Lee SK, Kong SY, Seong MW et al. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol 2009; 27:5088-93; PMID:19770372; http://dx.doi.org/10.1200/JCO.2009.22.4659
   PubMed Web of Science ®Google Scholar
• Rödel F, Wieland U, Fraunholz I, Kitz J, Rave-Frank M, Wolff HA, Weiss C, Wirtz R, Balermpas P, Fokas E et al. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Int J Cancer 2015; 136:278-88; PMID:24839133; http://dx.doi.org/10.1002/ijc.28979
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016; 16:275-87; PMID:27079802; http://dx.doi.org/10.1038/nrc.2016.36
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity 2016; 44:1069-78; PMID:27192570; http://dx.doi.org/10.1016/j.immuni.2016.04.023
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Serup-Hansen E, Linnemann D, Hogdall E, Bailey C, Summers J, Havsteen H, Thomas GJ. Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. Br J Cancer 2016; 114:134-7; PMID:26730577; http://dx.doi.org/10.1038/bjc.2015.448
   PubMed Web of Science ®Google Scholar
• Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006; 12:3355-60; PMID:16740757; http://dx.doi.org/10.1158/1078-0432.CCR-05-2434
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015; 75:2139-45; PMID:25977340; http://dx.doi.org/10.1158/0008-5472.CAN-15-0255
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Eng J Med 2010; 363:24-35; PMID:20530316; http://dx.doi.org/10.1056/NEJMoa0912217
   PubMed Web of Science ®Google Scholar
• Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28:4142-8; PMID:20697079; http://dx.doi.org/10.1200/JCO.2010.29.2904
   PubMed Web of Science ®Google Scholar
• Blitzer GC, Smith MA, Harris SL, Kimple RJ. Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2014; 88:761-70; PMID:24606845; http://dx.doi.org/10.1016/j.ijrobp.2013.08.029
   PubMed Web of Science ®Google Scholar
• Steel GG, McMillan TJ, Peacock JH. The 5Rs of radiobiology. Int J Radiat Biol 1989; 56:1045-8; PMID:2574214; http://dx.doi.org/10.1080/09553008914552491
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015; 16:e498-509; PMID:26433823; http://dx.doi.org/10.1016/S1470-2045(15)00007-8
   PubMed Web of Science ®Google Scholar
• Andersen AS, Koldjaer Solling AS, Ovesen T, Rusan M. The interplay between HPV and host immunity in head and neck squamous cell carcinoma. Int J Cancer 2014; 134:2755-63; PMID:23913554; http://dx.doi.org/10.1002/ijc.28411
   PubMed Web of Science ®Google Scholar
• Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res 2016; 22:2261-70; PMID:26819449; http://dx.doi.org/10.1158/1078-0432.CCR-15-2834
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Lopez-Soto A, Kumar S, Kroemer G. Caspases connect cell-death signaling to organismal homeostasis. Immunity 2016; 44:221-31; PMID:26885855; http://dx.doi.org/10.1016/j.immuni.2016.01.020
   PubMed Web of Science ®Google Scholar
• Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012; 2:95; PMID:22937524; http://dx.doi.org/10.3389/fonc.2012.00095
   PubMedGoogle Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105:93-103; PMID:21629244; http://dx.doi.org/10.1038/bjc.2011.189
   PubMed Web of Science ®Google Scholar
• Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001; 98:1667-77; PMID:11535496; http://dx.doi.org/10.1182/blood.V98.6.1667
   PubMed Web of Science ®Google Scholar
• Hu WH, Miyai K, Cajas-Monson LC, Luo L, Liu L, Ramamoorthy SL. Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. J Surg Oncol 2015; 112:421-6; PMID:26287957; http://dx.doi.org/10.1002/jso.23998
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The role of regulatory T cells in cancer immunology. Immunotargets Ther 2015; 4:159-71; PMID:27471721; http://dx.doi.org/10.2147/ITT.S55415
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015; 5:15179; PMID:26462617; http://dx.doi.org/10.1038/srep15179
   PubMed Web of Science ®Google Scholar
• Punt S, Dronkers EA, Welters MJ, Goedemans R, Koljenovic S, Bloemena E, Snijders PJ, Gorter A, van der Burg SH, Baatenburg de Jong RJ et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol Immunother 2016; 65:393-403; PMID:26899388; http://dx.doi.org/10.1007/s00262-016-1805-x
   PubMed Web of Science ®Google Scholar
• Nasman A, Romanitan M, Nordfors C, Grun N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T, Ramqvist T. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PloS One 2012; 7:e38711; PMID:22701698; http://dx.doi.org/10.1371/journal.pone.0038711
   PubMed Web of Science ®Google Scholar
• Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ, Kenter GG, van der Burg SH. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 2011; 128:379-89; PMID:20473854; http://dx.doi.org/10.1002/ijc.25361
   PubMed Web of Science ®Google Scholar
• Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016; 7:1486-99; PMID:26625204
   PubMed Web of Science ®Google Scholar
• Webb JR, Milne K, Nelson BH. PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. Cancer Immunol Res 2015; 3:926-35; PMID:25957117; http://dx.doi.org/10.1158/2326-6066.CIR-14-0239
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
   PubMed Web of Science ®Google Scholar
• Chapon M, Randriamampita C, Maubec E, Badoual C, Fouquet S, Wang SF, Marinho E, Farhi D, Garcette M, Jacobelli S et al. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol 2011; 131:1300-7; PMID:21346771; http://dx.doi.org/10.1038/jid.2011.30
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009; 27:1470-6; PMID:19224853; http://dx.doi.org/10.1200/JCO.2008.18.0513
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138:1429-40; PMID:19909745; http://dx.doi.org/10.1053/j.gastro.2009.10.057
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/10.1016/j.immuni.2007.09.006
   PubMed Web of Science ®Google Scholar
• Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegard J, Palmqvist R. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011; 24:671-82; PMID:21240258; http://dx.doi.org/10.1038/modpathol.2010.234
   PubMed Web of Science ®Google Scholar
• Nedergaard BS, Ladekarl M, Thomsen HF, Nyengaard JR, Nielsen K. Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer 2007; 97:1135-8; PMID:17940503; http://dx.doi.org/10.1038/sj.bjc.6604001
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370
   PubMed Web of Science ®Google Scholar
• Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F, Rödel C, Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014; 110:501-9; PMID:24129245; http://dx.doi.org/10.1038/bjc.2013.640
   PubMed Web of Science ®Google Scholar
• Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA, Soonawalla Z, Liu S, McKenna WG, Muschel RJ et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016; 7:40992-1004; PMID:27637082; http://dx.doi.org/10.18632/oncotarget.12022
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res 2016; 22:2848-54; PMID:26813359; http://dx.doi.org/10.1158/1078-0432.CCR-15-2010
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 2016; 47:52-63; PMID:26527522; http://dx.doi.org/10.1016/j.humpath.2015.09.003
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1:54-63; PMID:24416729; http://dx.doi.org/10.1158/2326-6066.CIR-13-0034
   PubMed Web of Science ®Google Scholar
• Morris VK, Ciombor KK, Salem ME, Nimeiri HS, Iqbal S, Singh PP, Polite BN, Deming DA, Chan E, Wade JL et al. NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). J Clin Oncol 34, 2016 ( suppl; abstr 3503)
   Google Scholar
• Helmke C, Raab M, Rödel F, Matthess Y, Oellerich T, Mandal R, Sanhaji M, Urlaub H, Rödel C, Becker S et al. Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. Cell Res 2016; 26:914-34; PMID:27325299; http://dx.doi.org/10.1038/cr.2016.78
   PubMed Web of Science ®Google Scholar